Jinhai Medical Technology (SEHK: 02225) has recently published its interim results for the first half of 2026, delivering a performance snapshot that carries notable highlights. The company has accelerated its revenue expansion while simultaneously improving profit quality.
During the first six months of 2026, the group recorded revenue of S$34.02 million, a substantial year-on-year increase of 134.16%, demonstrating robust sales momentum. Meanwhile, the loss attributable to shareholders narrowed to S$4.36 million, a reduction of 57.46% compared with the same period last year. This marked improvement in loss figures is primarily attributed to the explosive growth in its medical device-related operations. The company's revenue mix has undergone significant optimisation, with the strategic focus having successfully transitioned from traditional labour services to the high value-added medical device segment. Revenue generated from minimally invasive surgery solutions, medical products, and related service fees has climbed to 74.73% of total revenue, cementing its status as the new primary income pillar. Following solid growth in medical device sales revenue in 2025, this business segment surged by 301.5% year-on-year in the first half of 2026, reaching S$25.43 million, underscoring ample momentum for sustainable expansion. Concurrently, the company has made tangible strides in cost control and debt optimisation.
Administrative expenses were trimmed from S$12.5 million in the corresponding period last year to S$10.0 million, primarily driven by a reduction in share-based payments. As of 30 June 2026, the group held cash and cash equivalents of S$18.2 million, with liabilities at S$14.2 million, reflecting a steady decline from the end of 2025. The debt-to-asset ratio eased from 28.7% at the close of 2025 to 25.5%, signalling a continuously improving capital structure that provides a comfortable safety buffer for future research and development initiatives as well as market expansion efforts. Behind this operational growth lies the company's long-term commitment to technological R&D and sustained breakthroughs.
Notably, Jinhai Medical Technology's product portfolio now encompasses 4K ultra-high-definition endoscopy systems, 3D and glasses-free 3D image processing systems, 4K fluorescence and multispectral ultra-high-definition endoscopy systems, as well as 8K endoscopy systems, extending into complementary auxiliary equipment. This breadth forms a fully integrated closed-loop value chain spanning R&D, production, sales, and after-sales service. From an industry perspective, the ongoing upgrade of China's healthcare infrastructure, rising resident health consumption levels, and the growing adoption of early cancer screening practices continue to drive firm demand for minimally invasive diagnostics and treatment. Traditional open surgeries are increasingly giving way to minimally invasive procedures. This structural shift, which unlocks both replacement demand for existing procedures and incremental growth opportunities, provides a broad platform for the company's medium-to-long-term development.
To better align with the business expansion in minimally invasive treatments, the company appointed Mr. Ma Chengdong as Chief Marketing Officer in August this year. Mr. Ma previously held senior positions at multinational corporations including GE Healthcare and Medtronic, where he served as Sales Director and Senior Director of Greater China Marketing and Operations, combining a clinical medicine background with nearly three decades of hands-on marketing expertise. His appointment is expected to bring systematic market development capabilities and mature channel management experience to the company, accelerating its commercial expansion efforts. Overall, the explosive growth in the minimally invasive surgery solutions segment has validated the company's solid capabilities in product development and manufacturing. At the same time, the introduction of seasoned marketing talent signals that the company is rapidly strengthening its commercialisation capabilities. Looking ahead to the second half of 2026 and the longer term, should Jinhai Medical continue to capitalise on the rising penetration of minimally invasive surgery in China and the Asia-Pacific region while effectively navigating industry competition and policy uncertainties, it is well positioned to secure a more advantageous competitive standing in the import substitution process for domestically produced high-end medical equipment.
Comments